UACA Antibody (AE-5) [DyLight 350]

• Reactivity: Hu, Mu
• Applications: WB, Flow, ICC/IF
• Clone: AE-5
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: DyLight 350

UACA Antibody (AE-5) [DyLight 350] Summary

• Description: This conjugate is made on demand and is not held in inventory. Each order represents a unique lot. All conjugates are generated using validated conjugation protocols and meet strict degree of labeling (F/P) specifications; additional information is available upon request. The antibody concentration is provided on the individual product label.
  
  For specialized conjugation needs, like large quantities, specific concentrations, and defined F/P ratios, bulk and custom antibody conjugation services are available.
• Immunogen: Nuclei of myeloid leukemia biopsy cells
• Localization: Nuclear membrane
• Marker: Nuclear Membrane Marker
• Isotype: IgG1 Kappa
• Clonality: Monoclonal
• Host: Mouse
• Gene: UACA
• Purity: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Flow Cytometry
  • Immunocytochemistry/ Immunofluorescence
  • Western Blot
• Application Notes: Recommended applications are based on validated applications from the unconjugated base product NBP3-11314. This conjugated antibody is not kept in inventory and is made to order using validated conjugation protocols.

Packaging, Storage & Formulations

• Storage: Store at 4C in the dark.
• Buffer: 50mM Sodium Borate
• Preservative: 0.05% Sodium Azide
• Purity: Protein A or G purified

Notes

DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.

Alternate Names for UACA Antibody (AE-5) [DyLight 350]

• FLJ10128
• KIAA1561MGC141969
• MGC141967
• nuclear membrane binding protein
• NUCLING
• uveal autoantigen with coiled coil domains and ankyrin repeats
• uveal autoantigen with coiled-coil domains and ankyrin repeats

Background

UACA (uveal autoantigen with coiled-coil domains and ankyrin repeats) was originally identified as an autoantigen in patients with panuveitis, a characteristic of Vogt-Koyanagi-Harada disease, and in patients with Graves' disease. UACA was also later identified as Nucling, an mRNA differentially expressed in F9 embryonal carcinoma cells during cardiac muscle differentiation. UACA appears to function as a pro-apoptotic protein that recruits the apaf-1-pro-caspase-9 complex for the induction of apoptosis to mediate the cell-death pathway.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: UACA